The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Developments in personalized therapies for lung cancer
Alastair Greystoke, PhD, MBChB, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, discusses advances in personalized therapies for patients with lung cancer. The number of available treatments for specific mutations such as EGFR, ALK, ROS1, and MET exon 14 skipping mutant lung cancer have increased over the years. Targeted therapies for KRAS p.G12C–mutated lung cancer, as well as immunotherapies targeting PD-L1 have also meant more patients can access personalized therapies. Dr Greystoke additionally comments on need for wider adoption of liquid biopsies, which will improve detection and treatment outcomes. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Prof. Greystoke reports consultancy and speaker fees from AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen/ J and J, MSD, Novartis, Pfizer, Lilly, Takeda and Roche; and research funding from AstraZeneca. He is also the clinical Lead for Cancer North East England Hull and Yorkshire Genomic Laboratory Hub and a member of the National Test Directory Evaluation Working Group.
